Moleculera Labs

Moleculera Labs focuses on precision medicine, providing specialized blood-based autoantibody tests to identify immune dysfunction associated with chronic disorders, enhancing diagnostic capabilities for conditions such as neuropsychiatric and cardiovascular diseases. Moleculera Labs, founded by Craig Shimasaki and Madeleine Cunningham, specializes in precision medicine by offering advanced diagnostic tests. The company is headquartered in Oklahoma City, US. In May 2015, Moleculera secured USD 1.

06 mn in Series A funding from Oklahoma Seed Capital Fund and SeedStep Angels, which contributed to their growth. They have completed a total of 4 deals. Moleculera Biosciences specializes in precision medicine, primarily offering a range of blood-based autoantibody testing panels designed to identify underlying immune dysfunction in patients with chronic neuropsychiatric, cardiovascular, Long-COVID, and neuro-degenerative disorders. Their flagship product, the Autoimmune Brain Panel™, is a patented five-test series that aids clinicians in diagnosing whether neuropsychiatric symptoms stem from treatable autoimmune conditions.

The company has a robust pipeline that includes the Autoimmune Heart Panel™, Long-COVID Panel™, and Neuro-degenerative Disorder Panel™, which are all under development and will address critical gaps in the diagnosis and treatment of these disorders. Moleculera serves a diverse clientele, including over 2,500 clinicians and healthcare providers worldwide, focusing on markets in North America, Europe, and Asia. The integration of extensive biorepositories and AI-driven algorithms allows for the identification of biomarkers that further enhances the efficacy of the treatments provided. Revenue generation for Moleculera Biosciences is primarily driven by sales of its specialized testing panels to healthcare providers, which may involve a mix of direct-to-consumer services and B2B transactions.

Transactions typically occur through laboratory contracts with clinics and hospitals, where providers order the Autoimmune Brain Panel™ and other tests for patients exhibiting treatment-resistant neuropsychiatric symptoms. This model facilitates cash flow through predictable billing from healthcare professionals who rely on these advanced diagnostics to improve patient outcomes. The testing services are positioned to resolve key diagnostic challenges, thereby establishing Moleculera as an essential partner in managing chronic immune-mediated disorders. The company’s revenue is further supported by strategic collaborations, such as partnerships with organizations like Quest Diagnostics, aimed at broadening access to its innovative testing solutions.

Moleculera Labs plans to continue its growth trajectory through the introduction of new diagnostic products, including the upcoming Autoimmune Heart Panel™, Long-COVID Panel™, and Neuro-degenerative Disorder Panel™, which are currently under development. The company aims to expand its presence in North America, Europe, and Asia by targeting healthcare providers and institutions in these regions to enhance patient access to their testing solutions. The recent funding of USD 1. 06 mn raised in May 2015 will support these initiatives by providing the necessary capital for product development and market expansion efforts.